LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/Stryker’s “Big Easy” Poaching Lawsuit to Proceed in Michigan
Company News

Stryker’s “Big Easy” Poaching Lawsuit to Proceed in Michigan

December 1, 2015 2 min read Premium comments

Advertisement

Stryker’s “Big Easy” Poaching Lawsuit to Proceed in Michigan
Pixabay.com
Secondary

A federal judge in Michigan ruled on November 19, 2015 that a former New Orleans sales rep for Stryker Corporation must face the music of breach of contract and breach of fiduciary duty charges.

Christopher Ridgeway, the former rep, tried to make a technical argument that he worked for Stryker Leibinger, not Howmedica Osteonics, a Stryker subsidiary that is suing Ridgeway, and therefore only Leibinger could issue a non-compete agreement.

“Common-Law Rule of Reason”

The judge was having none of that. He said that Michigan does not prohibit non-compete agreements outside of the employer-employee context. “Michigan has a common-law rule of reason that contemplates the enforceability of non-competition agreements that qualify as reasonable.”

Ridgeway and Biomet Sued

Stryker fired Ridgeway on September 10, 2013 for allegedly engineering an elaborate scheme to take his Stryker customers to Biomet, Inc. Stryker then sued Ridgeway and Biomet for Breach of Contract and Fiduciary Duty, Misappropriation of Trade Secrets and Tortious Interference. In a 2013 article titled “Flippin’ Cakes and Poachin’ Reps in the Big Easy, “ we reported that Stryker said Ridgeway used secret code words to engineer the scheme. The “flipped” customers were allegedly referred to as “pancakes.”

Stryker claims that Ridgeway used his knowledge of Stryker’s confidential and proprietary information to enter the market and sell his genetic testing devices to Stryker’s customers and diverted Stryker’s funds to promote his personal business.

In early September 2013, Stryker said it learned that Ridgeway was devoting at least 50% of his time to operating two medical supply side businesses, through which he was “exploiting relationships with Stryker’s customers to sell other medical devices.” Stryker also said it learned that Ridgeway was requiring other Stryker employees to participate in such sales endeavors for his side businesses.

Advertisement

Non-Compete Questions

MassDevice reported that the judge also ruled that Ridgeway’s alternative argument, that the subsidiary not party to the non-compete should not be able to enforce it, should be aired out at trial.

“The evidence is sufficient to create an issue of fact as to whether Ridgeway was ever employed by Stryker Leibinger, ” wrote the judge. “Whether Ridgeway was ever employed by Stryker Leibinger, whether Stryker Leibinger had a reasonable competitive business interest justifying a non-compete agreement, whether the non-compete agreement was assigned to Howmedica Osteonics, and whether Stryker and Howmedica Osteonics were related or associated entities who could reasonably enforce the non-compete agreement all present questions of fact for trial.”

As for Stryker’s claim for breach of fiduciary duty, the judge found “sufficient evidence to create issues of fact as to whether Ridgeway had an agency relationship with Stryker and/or Howmedica Osteonics that would give rise to a fiduciary duty.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy